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Abstract 
The main aim of this study was to demonstrate that the surface immunogenic protein 
(Sip) of the aquatic pathogen Streptococcus agalactiae is a potential candidate for 
vaccine development for Oreochromis niloticus. In this study, a Sip was identified. 
Alignment analysis indicated that the Sip protein was highly homologous with Sip 
proteins from other S. agalactiae isolated from humans (99%). SDS-PAGE procedure 
indicated that the Sip protein was successfully expressed in Escherichia coli BL21 (DE3). 
The recombinant Sip protein was purified by affinity chromatography, and the mouse 
anti-Sip serum was produced. Tilapia Oreochromis niloticus were vaccinated with Sip, 
and immunogenicity was confirmed by subsequent western blotting. Enzyme-linked 
immunosorbent assay (ELISA) analysis demonstrated that Sip produced an observable 
antibody response in all sera of the vaccinated fish. The relative percentage survival (RPS) 
value for the Sip vaccine was 90.62. Tilapia vaccinated with Sip produced specific 
antibodies, and were highly resistant to infection by the virulent S. agalactiae. These 
results indicate that Sip is an effective vaccine candidate against S. agalactiae for tilapia, 
Oreochromisniloticus. 
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Introduction 
Streptococcus spp. is considered to be a diverse group, ranging from commensal 
organisms which occupy various niches of the human body to pathogens that infect a 
wide range of hosts. Streptococcus agalactiaeis is considered a pathogen responsible for 
causing infections in different animals, poultry, fish, rodents, mammals, and humans 
(Elliott et al., 1990; Evans et al., 2002; Evans et al., 2000; Evans et al., 2006; Hetzel et 
al., 2003; Yildifim et al., 2002a; Yildifim et al., 2002b; Zappulli et al., 2005). S. 
agalactiae infections can cause severe economic losses in wild and cultured hybrid tilapia 
(Oreochromis niloticus × Oreochromis aureus) worldwide (Wu et al., 2013). Control of 
streptococcosis through antibiotic treatment is not always successful and may harm the 
environment since resistant bacteria may be produced and transferred to aquatic animals 
or humans. Therefore, the development of vaccines to protect aquatic animals against 
streptococcosis is important (Kasper et al., 1996; Wessels et al., 1995). 
    Based on the composition of the capsular polysaccharide, S. agalactiae can be divided 
into ten serotypes (Ia, Ib and II to IX) (Chaffin et al., 2000; Persson et al., 2004; 
Slotved et al.,2007). Only serotype Ib has been detected and reported in fish 
(Vandamme et al., 1997). An alternative strategy for protecting fish would be to develop 
a vaccine based on a ubiquitous protein. Bacterial surface proteins have numerous 
advantages for vaccine development. Indeed, such bacterial proteins have been shown to 
be present in most pathogenic strains where they induce cross-protective immunity 
(Fikrig et al., 1990; Martin et al., 1997). Furthermore, these proteins do not need to be 
conjugated to other molecules, since they elicit an effective T-cell dependent antibody 
response resulting in long-term immunity (Brodeuret al., 2000). S. agalactiae surface 
proteins, already being investigated as potential vaccine candidates, are the Rib protein, 
the α and β subunits of the c protein, and the Rib protein (Flores & Ferrieri., 1989; 
Gravekamp et al., 1999; Stålhammar-Carlemalm et al., 1993). All these proteins are 
capable of eliciting antibodies in mice and to some extent prolong life and protect against 
lethal bacterial infections. 
  Bernard et al. (2000) identified a surface immunogenic protein (Sip) by immunological 
screening of a genomic library. Sip was identified in S. agalactiae strains representing all 
nine serotypes. Importantly, immunization of mice with purified recombinant Sip protein 
elicited protective immunity against lethal infection with S. agalactiae strains of several 
serotypes (Brodeur et al., 2000). This data indicates that Sip is an interesting candidate 
for the development of a protein-based vaccine against S. agalactiae disease.  
Oreochromis niloticus is an important species in commercial fisheries in southern 
China, particularly in the Guangdong province. It is also a species commonly found in 
brackish water in estuaries around the world (Vijayan et al., 1996). With the expansion 
and intensification of fish farming, disease outbreaks have increased and are recognized 
as a significant limitation on sustainable aquaculture (Bondad-Reantaso et al. 2005). One 
of the primary causes of disease in many aquaculture systems is bacterial infection, 
streptococcosis being the most common in cultured O.niloticus. Therefore, protecting 
cultured fish from disease is essential for the expansion and sustainability of the 
aquaculture industry. We investigated the potential of a 53-kDa protein, Sip to protect 
O.niloticus against experimental infection with S. agalactiae ZQ0910.  
 
Materials and Methods 
Bacteria and culture conditions. S. agalactiae strain ZQ0910 was isolated from diseased 
tilapia, O. niloticus in Zhaoqing City of Guangdong Province in China. The isolate was 
cultured overnight in Brain Heart Infusion (BHI, Huankai) at 37 0C in the presence of 8% 
CO2. Escherichia coli strains DH5α and BL21 (DE3) were cultured on Luria-Bertani (LB, 
Oxford) medium with 1.5% (w/v) agar at 37 0C. When required, the medium was 
supplemented with 100 μg/ml ampicillin (LB medium). Plasmid pMD-19T vector (Takara, 
Japan) was used for sequencing. The pET-32a(+) plasmid which contains a T7 promoter, 
Trx coding sequence, His-Tag sequence, and an ampicillin resistance gene was used for 
recombinant expression of Sip. 
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Extraction of genomic DNA. S. agalactiae strain ZQ0910 was preserved in Brain Heart 
Infusion (BHI, Huankai) incubated at 37 0C in the presence of 8% CO2. Genomic DNA was 
extracted by MiniBEST Bacterial Genomic DNA Extraction Kit (Takara). 
 Gene cloning and plasmid construction. The SIP genes from the strain ZQ0910 were 
amplified from purified chromosomal DNA by PCR with recombinant Taq DNA polymerase 
(Takara, Japan) as described by the manufacturer. The primers (PA1:5'-
ATGAAAATGAATAAAAAGGTACT-3') and (PA2: 5'-TTATTTGTTAAATG ATACGTGAACG -3') 
were designed according to the published sequence of SIP gene of S. agalactiae ZQ0910 
(GenBank accession no. AKAP01000043.1). Polymerase chain reaction (PCR) was 
performed for 4 min at 95 0C, 30 cycles for 60s at 94 0C, 30s at 57 0C  and 60s at 72 0C, 
and a final elongation period of 10 min at 72 0C. The products obtained after 
amplification were sequenced for the SIP gene from strain ZQ0910, then ligated into 
pMD-19T vector. The recombinant plasmid containing the SIP gene was named pMD-sip 
and transformed into E. coli DH5a. The sequence of the insert was also verified. To 
obtain a thioredoxin-Sip fusion protein with an N-terminal polyhistidine tag; the SIP gene 
was also amplified by PCR using primers (PB1:5'-
CGCGGATCCATGAAAATGAATAAAAAGGTACT-3') and (PB2:5'-ACGCGTCGA 
CTTATTTGTTAAATGATACGTGAACG-3'), which contained BamH I and Sal I restriction 
sites, respectively, and were used to perform the amplifications. The amplification 
product was ligated into plasmid pET-32a(+), and after sequencing, the recombinant 
plasmid named pET-Sip was transformed into E. coli  BL21(DE3). 
 Purification of the recombinant Sip protein. The E. coli BL21(DE3) cells containing 
recombinant plasmids were inoculated at a ratio of 1:100 (v/v) into Luria-Bertani broth 
(LB, Huankai) with antibiotics, were vigorously shaken, and incubated at 370C until the 
OD600 value reached 0.6. Then isopropylthio-β-D-galactoside (IPTG) was added to the 
culture at 1 mM concentration and incubated at 37 0C for 4 h. The bacteria were then 
collected after centrifugation at 4000g for 10 min. The pellets were re-suspended in 15 
ml of pH 7.4 lysis buffer (20 mM PBS, 0.5 M NaCl and 8 M urea). The cell suspension was 
then sonicated, and the lysed mixture was centrifuged at 12000 g for 10 min at 4 0C. The 
supernatant was then collected and filtered through a 0.22-μm spin filter (Ultrafree-MC, 
Millipore). The fusion protein was purified by affinity chromatography using a nickel-
charged resin (Ni-nitrilotriacetic acid Superflow: Qiagen Inc., Mississauga, Canada) 
following the manufacturer‟s instructions. The purity of the recombinant Sip protein was 
evaluated by SDS-PAGE, and the amount of protein was determined by bicinchoninic acid 
(BCA) assay according to manufacturer‟s instructions (Pierce Chemical Company, 
Rockford, III). 
 Vaccine preparation and vaccination. The purified recombinant Sip (1 mg/ml) and 
sterile PBS (10 mM, pH7.2) were emulsified with an equal volume of Freund‟s incomplete 
adjuvant (Sigma, USA). O.niloticus weighing approximately 30g were randomly divided 
into two groups, 120 fish per group. The vaccination group was immunized by 
intramuscular injection with the emulsified recombinant Sip, and the control group with 
emulsified sterile PBS. After vaccination, fish were maintained at 25 0C and fed 
commercial dry pellets daily. 
 Generation of a Sip-polyclonal antibody (Sip-PcAb). BALB/c mice (Guangdong medical 
college, Zhanjiang, China) were injected subcutaneously (s.c) three times at 3-week 
intervals with 50μg of purified recombinant thioredoxin-Sip protein in 0.1ml of PBS mixed 
with 50μg of Freund‟s adjuvant (Sigma, USA). Freund‟s complete adjuvant was used in 
the first injection and Freund‟s incomplete adjuvant was used in all subsequent 
injections. The mouse anti-Sip serum was collected on the seventh day after the fourth 
immunization. Simultaneously, the negative serum was produced as control by 
immunizing mice with PBS and Freund‟s adjuvant (Sigma, USA) using the same 
procedures. 
 Western blot analysis. Cultures of recombinant plasmid pET-Sip (transformed into E. 
coli BL21 cells) were centrifuged at 10,000 rpm for 1 min. The pellets were washed twice 
with phosphate buffered solution (10 mM, pH7.2) and re-suspended in PBS (10 mM, 
pH7.2). The cell suspension was boiled at 100 0C for 5 min. The crude protein extracts 
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were electrophoresed by SDS-PAGE containing 5% stacking gel and 12% separating gel. 
The expression of recombinant Sip protein was examined with  Western blot analysis 
using mouse anti-Sip serum (1:10,000) as the primary antibody and HRP- conjugated 
goat anti-mouse IgG (1:500, Sigma Co) as the secondary antibody. Simultaneously, the 
normal mouse serum was used as negative control. Western blot analysis was also 
carried out using His-tag monoclonal antibody (1:2000, Sigma Co) as primary and HRP- 
conjugated goat anti-mouse IgG (1:500, Sigma Co) as secondary antibody to detect 
whether the fusion protein with His-tag was successfully expressed. The antibody-bound 
proteins were then visualized by 3, 3'-di-aminobenzidine (DAB). 
 Analysis of antibody levels. Nine fish from each treatment group (vaccinated and 
control) were examined weekly for 7 weeks post-vaccination for antibody response 
against Sip by enzyme-linked immunosorbent assay (ELISA). 96-well plates were coated 
with the purified recombinant Sip (8μg/ml diluted in the preliminary assay). Two-fold 
serial dilutions of the fish serum were added to duplicate wells of the plates. Antibody 
binding to the antigen was detected using mouse anti-Tilapia (O. niloticus) IgM 
monoclonal antibody (Aquatic Diagnostics Ltd, Scotland), followed by horse radish 
peroxidase (HRP)-conjugated Goat-anti-mouse IgG at 1:4000 dilution. The reaction was 
developed with the 3,3,5,5-tetramethylbenzidine (TMB) substrate in H2O2 and stopped 
with 2.0M H2SO4. Optical density was measured at 450 nm using a microplate reader 
(μQuart, BioTek). Results were considered positive if the absorbance was at least double 
the control serum, and antibody titers were scored as the highest positive dilution. 
 Bacterial challenge experiments. Virulent S. agalactiae strain ZQ0910 was cultured at 
37 0C in BHI medium for 18h. Four weeks post-vaccination, fish in each group (100 per 
group) were used for the challenge test. Bacterial suspension of S. agalactiae strain 
ZQ0910 was prepared and adjusted to a cell density of approximately 1×108 cfu/ml. The 
fish were anesthetized and challenged by intraperitoneal inoculation with 0.1 ml of 
1×108cfu/ml (1×107cfu/ml per fish) cell suspension according to a preliminary 
experiment. Each sub-group of fish was then maintained in a separate tank with fresh 
running water at 25 0C for 14 d. Dead fish were autopsied to determine cause of death 
and to detect the presence of S. agalactiae in the tissues by bacterial culture in Brain 
Heart Infusion broth (BHI) agar. Relative percentage survival (RPS) was calculated from 
the cumulative mortalities using: 
  
mortality of vaccinated group
(1 ) 100%
mortality of control group
RPS   
  
 
Data are expressed as mean±SD. Statistical analysis was performed to assess serum 
antibody levels and mortality for significance (P<0.05) using student‟s t test. Probabilities 
of 0.05 or less were considered statistically significant. 
 
Results 
Cloning and sequence analysis. The open reading frame (ORF) sequence of Sip containing 
1305 nucleotides was obtained from the genome DNA of S. agalactiae strain ZQ0910 
using PCR and sequencing. The deduced amino acid sequences of SIP gene consisted of 
433 amino acid residues with predicted molecular weight of 45.5kDa. GenBank accession 
no. is AKAP01000043.1. 
BLAST analysis showed that the Sip sequence of S. agalactiae was highly similar to 
the homologous genes of other Streptococcus spp. in the GenBank database (ranging 
from 99-100% identity at DNA level, 98-100% identity at deduced amino acid level). The 
result of multiple amino acid sequence alignment analysis also indicated that they were 
highly conserved (Fig.1). 
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Figure 1. Multiple amino acid sequence alignment of Sip from Streptococcus agalactiae ZQ0910 and 
other strains. Identical amino acid residues presented were boxed in black, and boxes in grey 
indicated the location of similar residues. 
 
Expression and purification of the recombinant Sip. The predicted molecular mass 
of the Sip protein is 45.5 kDa, and the actual molecular mass of recombinant Sip protein 
seen in SDS-PAGE is 65.9 kDa because of the fusion protein which consists of 20.4kDa 
TRX-His-Stags. Western bolt analysis showed that His-Tag monoclonal antibody 
specifically recognized the Sip fusion protein expressed in E. coli. BL21. SDS-PAGE 
analysis showed that the His-tagged Sip protein was homogeneously purified because 
only a single band was detected in the electrophorogram (Fig. 2). 
 
Figure 2 Streptococcus 
agalactiae SDS-PAGE 
profile of Sip. Lanes: M, 
molecular mass markers; 
1, pET-32a (+) with IPTG 
induction; 2, pET-32a (+) 
without IPTG induction; 3, 
pET-sip without IPTG 
induction; 4, pET-sip with 
IPTG induction 
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Western blot analysis. Western blot analysis revealed that the prepared mouse 
anti-Sip serum did not react specifically to the Sip fusion protein, but also to natural Sip 
protein of S. agalactiae, while the normal mouse serum as negative control did not react 
to the Sip fusion protein (Fig 3).  
 
 
 
 
The ELISA results indicated that the titer of antisera was 1:512, 000. 
Analysis of serum antibody levels. The antibody production against the Sip of S. 
agalactiae in Tilapia is shown in Fig. 4.  
 
 
 
 
 
 
The results show that a specific antibody titer against Sip was detected in all sera of the 
vaccinated fish. During weeks 1 to 10 post-vaccination, log2 (antibody titers) in the sera 
of the vaccinated groups reached levels above 6.0, (the maximum reached was 14.0), 
while that of the control group was only 1.0-3.0 at all times. There was a significant 
difference (p < 0.01) in antibody titers between the vaccinated and control group  
 
 
 
 
 
 
 
 
Figure 3 Western blot analysis of 
pET-Sip expression in Escherichia 
coli BL21(DE3). Lanes M: 
prestained protein marker; Lane 1: 
the whole cell lysates of 
Streptococcus agalactiaeZQ0910 
(using mouse anti-Sip serum as the 
primary antibody); Lane 2: pET-Sip 
with IPTG induction (using mouse 
anti-Sip serum as the primary 
antibody); Lane 3: pET-Sip with 
IPTG induction (using normal 
mouse serum as the primary 
antibody). 
 
 
Figure 4 Analysis of serum 
antibody levels against Sip 
in Streptococcus 
agalactiae. Each bar 
represents mean log2 value 
± SD of the highest dilution 
of the serum when P/N 
≥2.7 (P/N= OD450 of the 
inspected sera/ OD450 of the 
negative serum). 
Significant differences from 
the control were P<0.05 
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Efficacy of the Sip vaccine. The cumulative mortality of Tilapia is shown in Table 1. 
 
Table 1. Cumulative mortality rate for Tilapia (Oreochromis niloticus) after challenge with S. agalactiae. 
Days after 
challenge  
Vaccinated group Control group 
No. of dead fish     Mortality rate,% No. of dead fish   Mortality rate, % 
1 0 0 0 0 
2 0 0 0 0 
3 0 0 10 10 
4 0 0 20 20 
5 0 0 26 26 
6 2 2 34 34 
7 2 2 38 38 
8 4 4 42 42 
9 7 7 71 71 
10 8 8 78 78 
11 8 8 90 90 
12 9 9 90 90 
13 9 9 93 93 
14 9 9 96 96 
 
The fish immunized with the Sip vaccine demonstrated a high level of protection. Results 
showed that after challenge with S. agalactiae fish mortality rate in the vaccinated 
groups was significantly lower (P < 0.01) than in the control group. The dead fish 
displayed disease symptoms typical of streptococcal infection. Abnormal behaviors 
included erratic swimming, swimming and whirling on the surface; ocular abnormalities 
included opacity, periorbital and intraocular hemorrhage, purulence and exophthalmia; 
reddening and hemorrhaging in the integumental and muscoskeletal system was 
common. In addition, typical of streptococcal infection, opercula were clear creating a 
„window to the gill‟ and no pathogen other than S. agalactiae was isolated. The RPS value 
for the Sip vaccine was 90.62. 
 
Discussion 
Some GBS surface proteins, such as the R protein, the α and β subunits of the C protein, 
and the Rib protein (Flores et al.,1989; Michel et al.,1991; Stålhammar-Carlemalm et al., 
1993), have been investigated as potential vaccine candidates. Unfortunately, these 
proteins were not found to be present in all clinical isolates (Ferrieri & Flores., 1997; 
Stålhammar-Carlemalm et al., 1993). A surface immunogenic protein (Sip), has been 
identified (Bernard R et al. 2000). Since Sip-specific antibodies efficiently recognized 
surface exposed epitopes on GBS cells, antibodies against these particular epitopes could 
play a role in antibody-mediated protective immunity (Rioux et al., 2001). This immunity 
appears to be important in preventing GBS infection. In this study, SIP gene was cloned 
and identified from S. agalactiae ZQ0910. The BLAST result showed that the putative 
amino acid sequence of SIP gene was conserved among different Streptococci strains. 
The multiple amino acid sequence alignment analysis indicated there were discernible 
similarities at the amino- and carboxy termini, while the central region was more diverse, 
reflecting the functional importance of the terminal amino acids in forming the tertiary 
structure of the Sip protein monomers. In additional, this could be one of the important 
reasons that Sip are particularly attractive and used for the development of vaccines. 
The Sip protein of S. agalactiade was successfully expressed and purified. When 
mouse polyclonal antibodies against the recombinant Sip were tested in Western blot 
with crude Sip, and the isolated Sip, a strong reaction was observed. Thus the 
recombinant Sip of S. agalactiae retained natural antigenicity. Therefore, we presume the 
recombinant Sip could be used as potential vaccine.  
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There is evidence that indicates that antibodies directed against GBS surface proteins 
conferring protective immunity are sufficient to prevent GBS infection (Larsson et al., 
1999; Michel et al., 1991; Stålhammar-Carlemalm et al., 1993). The present study 
suggests that a strong antibody response was induced and significant protection was 
achieved by vaccination with the Sip of S. agalactiae in mice. The immune response 
induced after immunization with recombinant Sip efficiently protected mice against 
experimental infection with different GBS strains, which included representatives of all 
nine serotypes (Riouxet al., 2001). It has been proven that recombinant Sip of S. 
agalactiae isolated from humans could provide protection for mice, and its RPS was 89 
(Brodeuret al., 2000). In our study, tilapia (Oreochromis niloticus) vaccinated with the 
isolated Sip of S. agalactiae were protected with a RPS of 94.  
The development of a versatile vaccine that provides heterologous protection for S. 
agalactiae has been a major concern because the pathogen has different serotypes. 
Recently more attention has been focused on the possibility of developing vaccines based 
on genetically conserved antigens present mainly in S. agalactiae, and all their serotypes. 
Such proteins would not only induce more effective and durable immune responses but 
also could potentially protect against all clinically relevant pathogens and their serotypes 
(Cai et al., 2013). Sip is an interesting candidate for the development of a protein-based 
vaccine against S. agalactiae disease. In this study, we applied the Freund‟s incomplete 
adjuvant in Sip vaccine as previously reported (Li et al., 2010). However, Freund‟s 
adjuvant was not applied in fish vaccines because of the cost and induced inflammation 
in the injection site (Sobhana et al., 2002). We plan to test the oil adjuvant in the future. 
In conclusion, the SIP gene from S. agalactiae was cloned and expressed in E. coli. 
This recombinant Sip is a protective antigen of S. agalactiae in O.niloticus. The present 
report confirms that Sip is exposed at the surface of intact S. agalactiae cells. Most 
importantly, the surface exposure of Sip is not hindered by other surface antigens. These 
observations promote further interest in Sip as a potential vaccine candidate against 
infection by S. agalactiae in O.niloticus. 
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